A registry study of patients with primary progressive MS has indicated that a longer exposure to disease modifying therapies (DMTs) is associated with a delay in time to wheelchair use.
Specialists from centers across Italy analyzed data on 1,214 patients in the Italian MS Registry with at least three evaluations using the Expanded Disability Status Scale (EDSS), and at least 3 years follow-up. They used models to assess how DMT use affected the risk of reaching EDSS 6 and 7 (severe disability).